Synthetic Biologics to Host Conference Call and Webcast to Discuss 2021 Year End Operational Highlights and Financial Results
Synthetic Biologics (NYSE American: SYN) announced a conference call on March 16, 2022, to discuss its financial results for the year ending December 31, 2021, and provide a corporate update. The call will begin at 4:30 p.m. ET, with participants encouraged to dial in 15 minutes early. The company is focused on developing therapeutics for unmet medical needs and has recently entered an agreement to acquire VCN Biosciences, which is working on an oncolytic adenovirus platform for cancer treatment.
- Acquisition of VCN Biosciences, enhancing oncolytic therapy potential.
- Development of SYN-004 and SYN-020 candidates targeting significant health challenges.
- None.
ROCKVILLE, Md., March 10, 2022 (GLOBE NEWSWIRE) -- Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company developing therapeutics designed to treat diseases in areas of high unmet need, today announced that it plans to host a conference call on Wednesday, March 16, 2022, at 4:30 p.m. ET to discuss its financial results for the year ended December 31, 2021 and provide a corporate update.
Individuals may participate in the live call via telephone by dialing (877) 451-6152 (domestic) or (201) 389-0879 (international) and using the conference ID: 13727535. Participants are asked to dial in 15 minutes before the start of the call to register. Investors and the public can access the live and archived webcast of this call via the “News & Media” section of the company’s website, https://www.syntheticbiologics.com, under “Events” or by clicking here, for 90 days after the call.
About Synthetic Biologics, Inc.
Synthetic Biologics, Inc. (NYSE American: SYN) is diversified clinical-stage company developing therapeutics designed to treat diseases in areas of high unmet need. The Company recently announced it has entered into a definitive agreement to acquire VCN Biosciences, S.L. (VCN), which is developing a new oncolytic adenovirus (OV) platform designed for intravenous (IV) and intravitreal delivery to trigger tumor cell death, improve access of co-administered cancer therapies to the tumor, and promote a robust and sustained anti-tumor response by the patient’s immune-system. In addition, the Company's lead candidates are: (1) SYN-004 (ribaxamase) which is designed to degrade certain commonly used IV beta-lactam antibiotics within the gastrointestinal (GI) tract to prevent (a) microbiome damage, (b) Clostridioides difficile infection (CDI), (c) overgrowth of pathogenic organisms, (d) the emergence of antimicrobial resistance (AMR), and (e) acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant (HCT) recipients, and (2) SYN-020, a recombinant oral formulation of the enzyme intestinal alkaline phosphatase (IAP) produced under cGMP conditions and intended to treat both local GI and systemic diseases. For more information, please visit Synthetic Biologics' website at www.syntheticbiologics.com.
For further information, please contact:
Investor Relations:
Chris Calabrese
LifeSci Advisors, LLC
ccalabres@lifesciadvisors.com
+1-917-680-5608
FAQ
What is the date of the Synthetic Biologics conference call?
What financial results will Synthetic Biologics discuss in their call?
What is the stock symbol for Synthetic Biologics?
What is the purpose of the Synthetic Biologics conference call?
What acquisition did Synthetic Biologics recently announce?
